A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs AZD 5363 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Nov 2015 Preliminary results from CTPs 700060691 and 700198780 presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
    • 01 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Apr 2013 Results will be presented at AACR, according to an Astex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top